PatentsUSA
Moderna agrees to pay $950 million upfront and up to $1.3 billion more contingent on appeal outcome in dispute over lipid nanoparticle technology, preserving key legal question on…
Moderna Inc. has reached a landmark settlement with Arbutus Biopharma and Genevant Sciences over patent infringement claims related to lipid-nanoparticle technology used in its Covid-19 vaccine. The agreement limits Moderna’s total liability to $2.25 billion and includes a planned appeal to the Federal Circuit on the…
PatentsUSA
Global agreement resolves U.S. and international litigation on lipid nanoparticle technology used in COVID-19 vaccines, averting imminent Delaware jury trial
Moderna, Genevant Sciences, and Arbutus Biopharma have finalized a global settlement addressing patent infringement claims related to lipid nanoparticle (LNP) delivery technology integral to Moderna’s COVID-19 vaccines. The deal includes an upfront payment of $950 million and potential additional payments up to $1.3 b…
PatentsUSA
The company targets patent eligibility, PTAB reform, and injunction rules as Congress advances bipartisan legislation to bolster IP protections in the display technology sector.
Intellectual Keystone Technology LLC has ramped up its lobbying activities in Washington, D.C., advocating for stronger patent protections aligned with ongoing congressional debates. With $2.16 million spent since early 2023, the company focuses on patent eligibility standards, PTAB reforms, and enforcement mechanisms…
PatentsUSA
SecureNet Solutions Group files suit in US Court of Federal Claims over biometric and video analysis technologies used in immigration enforcement and protest monitoring
SecureNet Solutions Group LLC has initiated a federal lawsuit accusing the Department of Homeland Security, Immigration and Customs Enforcement, and Customs and Border Patrol of infringing five patents related to video data analysis and biometric systems. The complaint highlights the use of facial recognition, license…
PatentsGlobal
Patents bolster Genprex’s global IP portfolio, supporting ongoing Acclaim-3 clinical trial for small cell lung cancer with PD-L1 and PD-1 antibody combinations
Genprex, Inc. has obtained favorable patent grants from the Japanese Patent Office and European Patent Office covering the use of its REQORSA gene therapy in combination with PD-L1 and PD-1 antibodies to treat cancer. These patents reinforce Genprex’s intellectual property rights in major markets and underpin its Accl…
PatentsUSA
High Court to address whether generic drug makers’ broad marketing of ‘skinny label’ generics triggers induced infringement claims under patent law
The U.S. Supreme Court has granted certiorari in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. to clarify when advertising a generic drug as a ‘generic’ for a patented brand-name drug can lead to liability for induced patent infringement. The case focuses on ‘skinny label’ generics approved for non-patented us…
PatentsUSA
Hikma Pharmaceuticals v. Amarin Pharma spotlights limits on generic drug promotion and patent infringement under Hatch-Waxman’s skinny labeling provisions
The U.S. Supreme Court has granted certiorari in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. to resolve whether generic drug makers’ marketing statements can support inducement claims of patent infringement when using skinny labels that omit patented uses. The case tests the boundaries of Hatch-Waxman’s Sect…
PatentsUSA
The pharmaceutical giant is accused of unlawfully monopolizing the market for its diabetes drug Victoza, prompting legal action in the United States.
Novo Nordisk has been sued for allegedly monopolizing the diabetes drug Victoza, with claims that the company engaged in anticompetitive practices to maintain exclusive control over the market. The lawsuit highlights concerns about market dominance and access to essential diabetes treatments.
TrademarksUSA
Corporate counsel anticipate stable patent litigation volumes in 2026 but warn of increased risks linked to third-party litigation financing
A recent survey by Norton Rose Fulbright of 400 US corporate counsel highlights a stabilization in patent dispute volumes while signaling potential risk escalation due to third-party funding in the coming year. The findings provide insight into evolving perceptions of intellectual property challenges across patents, t…
PatentsUSA
Global law firm White & Case LLP expands its intellectual property litigation capabilities by integrating a leading group of life sciences IP litigators.
White & Case LLP has bolstered its life sciences intellectual property litigation practice by adding a prominent team of litigators specializing in this sector. This strategic move enhances the firm’s capacity to handle complex patent disputes and IP enforcement within the life sciences industry, reinforcing its posit…
PatentsGlobal
Robust growth driven by IoT expansion, digital economy rise, and strategic partnerships amid evolving IP commercialization landscape
The international technology licensing market, valued at over $2.1 billion in 2025, is forecasted to grow at a compound annual growth rate (CAGR) of 11.7% from 2026 to 2035, reaching $5.6 billion. Key drivers include the proliferation of IoT devices, increasing digital economy adoption, and government-backed innovatio…
LitigationUSA
Wheatley’s landmark trademark victories and high-profile litigation underscore her leadership in IP law
Lucy Jewett Wheatley, partner at McGuireWoods and co-leader of its Intellectual Property Practice Group, has been named a 2025 Intellectual Property MVP by Law360 for the second time. Her notable achievements include a pivotal trademark infringement trial victory for Pennsylvania State University and successful repres…
PatentsUSA
Rapper Eminem files petition with USPTO to cancel Swim Shady’s trademark, alleging brand name infringes on his Slim Shady identity
US rapper Eminem has initiated legal proceedings against Australian beachwear company Swim Shady, claiming the brand’s name infringes on his trademarked rap alias Slim Shady. The dispute centers on a trademark granted to Swim Shady in the US, which Eminem seeks to cancel through the US Patent and Trademark Office. The…
LitigationGlobal
Fee-funded USPTO continues full operations without disruption, while federal courts and ITC face funding challenges amid shutdown, affecting patent and trademark litigation timeli…
The United States Patent and Trademark Office (USPTO), uniquely funded by fees, remains fully operational during the ongoing government shutdown, with no observed decline in patent application activity. However, federal courts handling intellectual property litigation are experiencing funding shortages that may lead t…
PatentsUSA
Foley & Lardner LLP secures affirmance of district court’s claim construction limiting patent terms to integral fastener-less connectors, defeating infringement allegations by Bar…
In a significant patent litigation victory, Foley & Lardner LLP successfully defended Fortress Iron LP and Fortress Fence Products LLC against infringement claims brought by Barrette Outdoor Living. The U.S. Court of Appeals for the Federal Circuit affirmed the Northern District of Texas’s claim construction, which co…
CopyrightUSA
Former President Donald Trump petitions the Supreme Court to permit the dismissal of the Copyright Office head, challenging existing protections.
Donald Trump has filed a petition with the U.S. Supreme Court requesting authorization to fire the head of the U.S. Copyright Office. This move raises significant questions about the statutory protections afforded to the Copyright Office director and the limits of presidential authority over this position. The case co…
LitigationUSA
New USPTO leadership shifts control of inter partes and post-grant review determinations away from the Patent Trial and Appeal Board
John Squires, the newly appointed director of the U.S. Patent and Trademark Office, announced a significant policy change by reclaiming the agency's authority to decide whether to institute inter partes and post-grant reviews. This move transfers decision-making power from the Patent Trial and Appeal Board back to USP…
LitigationUSA
Major studios challenge generative AI's use of copyrighted characters, seeking injunctions and licensing safeguards in landmark federal case
On June 11, 2025, The Walt Disney Company and Universal Studios filed a federal lawsuit against AI firm Midjourney, accusing it of copyright infringement for training its image-generation models on proprietary characters without authorization. The case, filed in California, spotlights the legal tensions between creati…